Veterinary Oncology Market size, Share, And Future Outlook
Veterinary Oncology Market Growth, Size, Trends Analysis- By Animal Type, By Therapy, By Cancer Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: May-2025 | Report ID: HLCA25153 | Pages: 1 - 255 | Formats*: |
| Category : Healthcare | |||
Veterinary Oncology Market Introduction and Overview
According to SPER Market Research, the Global Veterinary Oncology Market is estimated to reach USD 5.04 billion by 2034 with a CAGR of 12.36%.
The report includes an in-depth analysis of the Global Veterinary Oncology Market, including market size and trends, product mix, Applications, and supplier analysis. Key drivers of growth include the rising incidence of cancer in pets, increasing research efforts in veterinary oncology, and a heightened emphasis on animal health and safety. Cancer is a leading cause of death in both dogs and cats, particularly as they age. Many dogs are likely to develop abnormal tissue growth during their lifetime. Ongoing advancements in research and the growing investment in pet cancer treatments are expected to enhance available therapies and support the continued expansion of the market. However, The veterinary oncology market faces challenges such as high treatment costs, limiting accessibility for pet owners.
By Animal Type:
The canine segment dominates the market and is projected to grow rapidly, driven by the increasing prevalence of cancer in dogs and growing awareness of available treatments. A rising pet dog population and ongoing clinical trials targeting canine tumors are further boosting this segment. Meanwhile, the feline segment is also expected to experience notable growth, largely due to the increasing global cat population and the rising incidence of related health conditions.
By Therapy:
The surgery segment leads the market, as it remains the most effective option for removing tumors that are accessible and have not spread to vital areas. It is often the initial treatment choice for malignant cancers, especially when the tumor is low-grade and shows no signs of spreading. Successful surgical procedures can lead to remission without the need for further therapies, making surgery a preferred approach and a key contributor to market growth.
By End Use:
The skin cancer segment leads the market due to the high occurrence of conditions like squamous cell carcinoma in both cats and dogs. Skin tumors are particularly common in older dogs, while cats often develop such cancers on the face or toes. The growing prevalence of skin cancers across companion animals is driving the demand for early diagnosis and advanced treatment options, boosting market growth.
Regional Insights:
North America held the largest share of the veterinary oncology market, driven by growing efforts from leading companies to expand access to precision medicine for pet cancer treatment. Strategic partnerships in the region, such as the collaboration between Ardent and FidoCure, are enhancing innovation and expanding the availability of advanced oncology solutions. These initiatives leverage each partner’s strengths to improve care and accelerate progress in the veterinary oncology field.
Market Competitive Landscape:
The global Veterinary Oncology Market is moderately consolidated, with several prominent players shaping the industry. Key companies include: Elanco, Boehringer Ingelheim International GmbH, Zoetis, Elekta AB, PetCure Oncology, Accuray Incorporated, Varian Medical Systems, Inc. (parent company: Siemens Healthineers), Virbac, Merck & Co., Inc., Ardent Animal Health, LLC.
Recent Developments:
In September 2024, Boehringer Ingelheim International GmbH acquired Saiba Animal Health AG to expand its portfolio in animal therapeutics. This acquisition brings an advanced vaccine development platform that is anticipated to boost progress in the veterinary oncology field.
In March 2024, Merck & Co., Inc. finalized its acquisition of Harpoon Therapeutics, Inc., aiming to broaden and strengthen its oncology pipeline.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Animal Type, By Therapy, By Cancer Type |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Elanco, Boehringer Ingelheim International GmbH, Zoetis, Elekta AB, PetCure Oncology, Accuray Incorporated, Varian Medical Systems, Inc. (parent company: Siemens Healthineers), Virbac, Merck & Co., Inc., Ardent Animal Health, LLC. |
- Global Veterinary Oncology Market Size (FY 2021-FY 2034)
- Overview of Global Veterinary Oncology Market
- Segmentation of Global Veterinary Oncology Market By Animal Type (Canine, Feline, Equine)
- Segmentation of Global Veterinary Oncology Market By Therapy, (Radiotherapy, Surgery, Chemotherapy, Immunotherapy, Other Therapies)
- Segmentation of Global Veterinary Oncology Market By Cancer Type (Skin Cancers, Lymphomas, Sarcomas, Others)
- Statistical Snap of Global Veterinary Oncology Market
- Expansion Analysis of Global Veterinary Oncology Market
- Problems and Obstacles in Global Veterinary Oncology Market
- Competitive Landscape in the Global Veterinary Oncology Market
- Details on Current Investment in Global Veterinary Oncology Market
- Competitive Analysis of Global Veterinary Oncology Market
- Prominent Players in the Global Veterinary Oncology Market
- SWOT Analysis of Global Veterinary Oncology Market
- Global Veterinary Oncology Market Future Outlook and Projections (FY 2025-FY 2034)
- Recommendations from Analyst
1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
6. Competitive Landscape
- 6.1. Global Veterinary Oncology Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Veterinary Oncology Market
7. Global Veterinary Oncology Market, By Animal Type, (USD Million) 2021-2034
- 7.1. Canine
- 7.2. Feline
- 7.3. Equine
8. Global Veterinary Oncology Market, By Therapy, (USD Million) 2021-2034
- 8.1. Radiotherapy
- 8.1.1. Stereotactic Radiation Therapy
- 8.1.2. Conventional Radiation Therapy
- 8.2. Surgery
- 8.3. Chemotherapy
- 8.4. Immunotherapy
- 8.5. Other Therapies
9. Global Veterinary Oncology Market, By Cancer Type, (USD Million) 2021-2034
- 9.1. Skin Cancers
- 9.2. Lymphomas
- 9.3. Sarcomas
- 9.4. Others
10. Global Veterinary Oncology Market, (USD Million) 2021-2034
- 10.1. Global Veterinary Oncology Market Size and Market Share
11. Global Veterinary Oncology Market, By Region, 2021-2034 (USD Million)
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
12. Company Profile
- 12.1. Elanco
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Boehringer Ingelheim International GmbH
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Zoetis
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. Elekta AB
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. PetCure Oncology
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Accuray Incorporated
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Varian Medical Systems, Inc. (parent company: Siemens Healthineers)
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Virbac
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Merck & Co., Inc.
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. Ardent Animal Health, LLC
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
13.Conclusion
14.List of Abbreviations
15.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Veterinary Oncology Market is projected to reach USD 5.04 billion by 2034, growing at a CAGR of of 12.36% during the forecast period.
Veterinary Oncology Market grew in Market size from 2025. The Market is expected to reach USD 5.04 billion by 2034, at a CAGR of 12.36% during the forecast period.
Veterinary Oncology Market CAGR of 12.36% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Veterinary Oncology Market size is USD 5.04 billion from 2025 to 2034.
Veterinary Oncology Market is covered By Animal Type, By Therapy, By Cancer Type
The North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa is the highest Market share in the Veterinary Oncology Market.
Elanco, Boehringer Ingelheim International GmbH, Zoetis, Elekta AB, PetCure Oncology, Accuray Incorporated, Varian Medical Systems, Inc. (parent company: Siemens Healthineers), Virbac, Merck & Co., Inc., Ardent Animal Health, LLC.
The report includes an in-depth analysis of the Global Veterinary Oncology Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
